JOURNAL BACTERIOLOGY, 2007, p. 3721â€“3728                                                                                     Vol. 189,  10
0021-9193/07/$08.00â«¹0 doi:10.1128/JB.01740-06
Copyright Â© 2007, American Society Microbiology. Rights Reserved.



       Functional Complementation Essential Gene fabG1          Mycobacterium tuberculosis Mycobacterium smegmatis fabG
                       Escherichia coli fabGäŒ¤
                     Tanya Parish,1* Gretta Roberts,1â€  Francoise Laval,2 Merrill Schaeffer,3â€¡
                                     Mamadou DaffeÂ´,2 Ken Duncan,4Â§
 Centre Infectious Disease, Institute Cell Molecular Science, Barts London, London E1 2AT, United Kingdom1;
   Institut Pharmacologie et Biologie Structurale (UMR5089), Department Molecular Mechanisms Mycobacterial Infections,
     Centre National la Recherche Scientifique UniversiteÂ´ Paul Sabatier (Toulouse III), 205 Route Narbonne,
       F-31077 Toulouse Cedex, France2; GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 194263;                     GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom4
                                           Received 13 November 2006/Accepted 27 February 2007

            Mycolic acids key component mycobacterial cell wall, providing structure forming major
          permeability barrier. Mycobacterium tuberculosis mycolic acids synthesized type type II fatty acid
          synthases. enzymes type II encoded fabG1. demonstrate gene
          deleted M. tuberculosis chromosome functional copy provided 
          showing normal culture conditions fabG1 essential. FabG1 activity replaced           corresponding enzyme closely related species Mycobacterium smegmatis enzyme           Escherichia coli. M. tuberculosis carrying FabG M. smegmatis showed phenotypic changes,           mycolic acids cell wall permeability unchanged.  M. tuberculosis M. smegmatis enzymes           interchangeable control lengths types mycolic acids synthesized.


   mycobacterial cell wall complex lipid-rich struc-              acid synthase (FAS). FAS multienzyme, single-polypep-
ture composed outer layer mycolic acids covalently                    tide complex responsible novo synthesis C22
linked arabinogalactan, turn linked pepti-                   C26 fatty acids. FAS II composed number individ-
doglycan. structure surrounded outermost layer,                 ual enzymes, including enzymes encoded inhA fabG, â€œcapsule,â€? pathogenic species (8). work fo-                    elongate FAS products produce long-chain
cused understanding role biosynthesis com-                   fatty acids  review, reference 29).
ponents cell wall, particularly mycolic acids. Current                 Mycolic acids particular  biosynthesis
models propose mycolic acids form inner leaflet                   target antibiotics, isoniazid ethionamide. asymmetric bilayer outside peptidoglycan-arabino-                    number compounds, including triclosan thiolacto-
galactan layer, free lipids forming outer leaflet (5, 8).             mycin, affect mycolic acid biosynthesis inhibiting enzymes Numerous molecules, including important immune                       FAS II pathway. Global gene expression profiling drug
modulator lipoarabinomannan, outer                      treatment demonstrated isoniazid, thiolactomycin, layer. extremely hydrophobic layer forms important                     triclosan different effects cells permeability barrier reasons intrinsic               likely different modes action (2). Triclosan isoni-
resistance mycobacteria antibacterial agents.
                                                                               azid inhibit InhA (21), thiolactomycin inhibits KasA
   Mycolic acids â?£-alkyl, â?¤-hydroxy fatty acids                                                                                KasB (12, 15, 26, 27). debate concern-
alkyl chains, â€œshortâ€? chain (C22 C26) long â€œmero-
                                                                               ing primary target isoniazid, prodrug mycolateâ€? chain (Câ¬Ž50). Mycobacterium tuberculosis synthe-
                                                                               activated mycobacterial KatG catalase (13, 33, 34). 
sizes distinct types mycolic acids, alpha-, methoxy-,
                                                                                recent work demonstrated single point mutation keto-mycolic acids C24 C26 C54 C63                                                                                inhA reduces binding isoniazid-NAD adduct chains. Synthesis mycolic acids involves types fatty
                                                                               sufficient confer isoniazid resistance (31). Interestingly, isonia-
                                                                               zid inhibits FabG1 vitro (11).
  * Corresponding author. Mailing address: Centre Infectious Dis-             interested M. tuberculosis inhA operon,
ease, Institute Cell Molecular Science, Barts London,           consists genes, fabG1 (mabA), inhA, hemZ,
London E1 2AT, United Kingdom. Phone: 44 20 7882 2306. Fax: 44 20              cotranscribed polycistronic message (1). 7882 2189. E-mail: t.parish@qmul.ac.uk.
                                                                               previously demonstrated hemZ required heme bio-
  â€  Present address: Department Biosurgery & Surgical Technol-
ogy, Imperial College London, St. Maryâ€™s Hospital, Praed Street, Lon-          synthesis hemZ mutants hemin auxotrophs (22).
don W2 1NY, United Kingdom.                                                    intuitively expect inhA fabG1   â€¡ Present address: Boehringer Ingelheim Vetmedica, , 2621                essential genes, definitive genetic proof North Belt Highway, Saint Joseph, MO 64506.
                                                                               obtained. fact FAS II essential   Â§ Present address: Melinda Gates Foundation, P.O. Box
23350, Seattle, WA 98102.                                                      demonstrated Mycobacterium smegmatis, inactiva-
  äŒ¤
    Published ahead print 2 March 2007.                                  tion InhA KasA leads cell lysis (4, 31).  
                                                                        3721
 3722       PARISH ET AL.                                                                                                                               J. BACTERIOL.


                                                                TABLE 1. M. tuberculosis strains
                                      Description                                                                   Genotype

H37Rv                     Wild-type laboratory strain                                fabG1
Mess 4                    Single crossover                                           fabG1 fabG1âŒ¬ kan hyg lacZ sacB
Mess 10                   Merodiploid                                                fabG1 fabG1âŒ¬ kan hyg lacZ sacB å…³fabG1 inhA hemZ gm L5 intå…´
Mess 19                   Delinquent strain                                          fabG1âŒ¬ å…³fabG1 inhA hemZ gm L5 intå…´
Mess 25                   Switched strain (pDUCK1)                                   fabG1âŒ¬ å…³fabG1 inhA hemZ kan L5 intå…´
Mess 26                   Switched strain (pDUCK2)                                   fabG1âŒ¬ å…³fabG1 inhA hemZ hyg L5 intå…´
Mess 29                   Switched strain (pDUCK8)                                   fabG1âŒ¬ å…³fabG1 hyg L5 intå…´
Mess 27                   Switched strain (M. smegmatis fabG1)                       fabG1âŒ¬ å…³fabGMsm gm L5 intå…´
Mess 30                   Cointegrated strain                                        fabG1âŒ¬ å…³fabG1 inhA hemZ hyg L5 intå…´å…³fabGEcE233K,A154T gm L5 intå…´
Mess 31                   Cointegrated strain                                        fabG1âŒ¬ å…³fabG1 inhA hemZ hyg L5 intå…´å…³fabGEcA154T gm L5 intå…´
Mess 32                   Cointegrated strain                                        fabG1âŒ¬ å…³fabG1 inhA hemZ hyg L5 intå…´å…³fabGEcE233K gm L5 intå…´



results saturating transposon mutagenesis M. tuberculosis                     single PacI site cloning inserts) generate plasmids pDUCK15,
suggested kasA kasB essential growth,                        pDUCK16, pDUCK18, respectively.
                                                                                       switching experiment replace integrated pMabA-HemZ-Int vector inhA fabG1 (25). addition, mycolic acid-                        various versions alternative integrating vectors carried previ-
defective mutants M. smegmatis Mycobacterium bovis                           ously described (24). Mess 19 (Table 1) electroporated, transformants
BCG isolated (3, 18), suggesting mycolic acids                       isolated appropriate antibiotic selection  incoming vector). essential cell viability. order determine                      Transformants patch tested antibiotic resistance required.
                                                                                       Phenotypic analyses. Colony morphology assessed 7H10-OADC agar FAS II complex essential, investigated
                                                                                    plates (19 g literâ«º1 Middlebrook 7H10, 10  [vol/vol] oleic acid-albumin-dex- key genes, fabG1, encodes 3-keto-                        trose-catalase [OADC] supplement [Becton Dickinson]) antibiotics. acyl reductase (1), essential. examined specificity                  determine resistance isoniazid, M. tuberculosis strains plated 7H10- homologs fabG M. smegmatis Escherichia coli                         OADC agar plates containing various concentrations isoniazid (0, 0.01, 0.05,
determine complement function                         0.1, 0.5, 1, 5 â?®g mlâ«º1), growth scored 7 days. Growth                                                                                     monitored 5 ml 7H9-OADC-Tw liquid medium (4.7 g literâ«º1 Middlebrook
M. tuberculosis enzyme.                                                             7H9, 10  [vol/vol] OADC supplement, 0.05  [wt/vol] Tween 80) containing
                                                                                    various concentrations isoniazid (0, 0.01, 0.05, 0.1, 0.5, 1, 5 â?®g mlâ«º1);                         MATERIALS METHODS                                       cultures stirred 250 rpm 8-mm flea, growth monitored
                                                                                    21 days. Detergent sensitivity determined 7H9-OADC-Tw liquid
   Gene replacement M. tuberculosis. fabG1 deletion delivery vector                                                                                     medium 7H10-OADC agar plates. Growth curves obtained using
constructed amplifying flanking regions fabG1 using primers fabG1-1
                                                                                    12-mm-diameter borosilicate tubes containing 4 5 ml medium stirred
(AAG CTT GTA CTC GGC GAC GAC C) fabG1-2 (GTT TCC TCC GGT
                                                                                    250 rpm 8-mm flea.
AAC CAG) primers fabG1-3 (TAT ATC TCC GGT GCG GTC                                                                                         Mycolic acid analyses. Cultures grown late log phase 100 ml fabG1-4 (AAC AGG TAC CCG CGT CCA ACC GTT CG). Primers fabG1-1
                                                                                    7H9-OADC medium (containing Tween 80) autoclaved. Pellets fabG1-4 engineered carry HindIII KpnI sites (underlined).                                                                                     recovered extracted organic solvents (14). bacterial residues ob-
products cloned HindIII-KpnI sites p2NIL (23). PacI
                                                                                    tained lipid extraction saponified mixture 40  KOH cassette pGOAL19 (23) carrying hyg, lacZ, sacB inserted obtain
                                                                                    methoxyethanol (1:7, vol/vol) 110Â°C 3 h screw-cap tube (9). final vector, pFabG1 (data available request). step recombination
                                                                                    acidification, fatty acids extracted diethyl ether methylated method used isolate single-crossover strain (Mess 4) double
                                                                                    ethereal solution diazomethane. mycolate patterns strains crossovers subsequently (23). Double crossovers screened PCR using
                                                                                    determined analytical layer chromatography (TLC) Silica Gel 60
primers fabG1 (5â¬˜ CGG CCG CGG CGA GAC GAT AG 3â¬˜) fabG1 rev
                                                                                    (Macherey-Nagel) using eluent (petroleum ether-diethyl ether, 9:1
(5â¬˜ GGT CGC CGG CAG CCA GTC AGA 3â¬˜). complementing vector
                                                                                    [vol/vol]; runs) eluent B (dichloromethane). Lipid spots revealed pMabA-HemZ-Int (22), carrying complete fabG1 operon gentamicin
                                                                                    spraying plates molybdophosphoric acid (10  ethanol), followed resistance L5 integrating vector, used generate merodiploid strain
                                                                                    charring. crude mycolate fraction obtained precipitating ethereal
(Mess 10) (Table 1). Double crossovers isolated merodiploid
                                                                                    solution fatty acid methyl esters methanol 4Â°C, followed centrifu-
strain screened PCR described confirmed Southern
                                                                                    gation 4,000 â«» g 20 min (10). different classes mycolates hybridization.
                                                                                    separated preparative TLC using eluent  lengths various types    Switching experiments â€œdelinquentâ€? strain. Integrating vectors carrying
                                                                                    purified mycolates determined matrix-assisted laser desorption ioniza- fabG1 operon different resistance markers constructed (data
                                                                                    tionâ€”time flight (MALDI-TOF) mass spectrometry previously described
available request). pDUCK1 constructed cloning KpnI-HindIII
                                                                                    (17). spectra acquired reflectron mode Applied Biosystems
fragment pMabA-HemZ-Int pMV306 (kan) (28), pDUCK2                                                                                     4700 Analyser mass spectrometer (Applied Biosystems, Framingham, MA)
constructed replacing gm-int fragment pMabA-HemZ-Int                                                                                     equipped Nd:YAG laser (wavelength, 355 nm; pulse, â¬?500 ps; repetition
hyg-int HindIII cassette pUC-Hyg-Int (19). pDUCK8 carrying fabG1
                                                                                    rate, 200 Hz). total 2,500 shots accumulated positive ion mode, constructed amplifying M. tuberculosis gene primers Messy8 (5â¬˜
                                                                                    mass spectrometry data acquired using instrument default calibration.
GGT ACC ATG GAA ATC GAC TGG TCA GG 3â¬˜) Messy9 (5â¬˜ AAG TCC
                                                                                    Mycolate samples dissolved chloroform concentration 1 mM ATC GAC GAG TCG GTG ATG 3â¬˜), subcloning product pGEM-T
                                                                                    directly spotted target plate 0.5-â?®l droplets, followed addi-
Easy, adding hyg-int cassette pUC-Hyg-Int (19) HindIII
                                                                                    tion 0.5 â?®l matrix solution. Samples allowed crystallize room
fragment. M. smegmatis fabG native promoter amplified                                                                                     temperature. matrix used 2,5-dihydroxybenzoic acid (10 mg/ml) genomic DNA using primers MAP3 (5â¬˜ GGT ACC CCG CGC TTC TGA TCA
                                                                                    CHCl3-CH3OH (1:1, vol/vol).
ACC 3â¬˜) MAP4 (5â¬˜ AAG TCC TGA CTC CTT GTG AGC GAG AA 3â¬˜),
cloned pGEM-T Easy (Promega), excised EcoRI fragment, cloned L5 integrating vector pINT3 (22) obtain pDUCK9. E. coli fabG alleles amplified plasmids pCL33, pCL79, pCL80 (16) using primers                                 RESULTS DISCUSSION
Ec-FabG (5â¬˜ CCT TAA TTA AGC GCT CGA GCT TTA AAA GAG 3â¬˜) Ec-FabG-rev (5â¬˜ CCT TAA TTA ACA ACT AAA TCC CGG CAG GTC T
                                                                                      Essentiality M. tuberculosis fabG1. 3â¬˜). Products cloned PacI fragments (sites primers underlined)      work understanding biosynthesis mycolic acids 
pAPA3  derivative pINT3 carrying mycobacterial Ag85a promoter          cause key role cell wall mycobacteria  VOL. 189, 2007                                                                   FUNCTIONAL COMPLEMENTATION fabG1                       3723




  FIG. 1. Chromosomal arrangement fabG1 isolation mutant strains.   Chromosomal arrangement fabG1 M. tuberculosis.
Regions amplified delivery vector complementing vector indicated bars. (B) PCR screening double crossovers isolated merodiploid strain Mess 10. Primers fabG1 fabG1 rev used amplify fabG1 alleles; expected sizes 1.5 kb wild type 0.9 kb deletion. Lane 1, 100-bp marker; lane 2, lambda HindIII marker; lanes 3 18, double crossovers generated Mess 10; lane
19, Mess 10 (merodiploid); lane 20, Mess 4 (single crossover).



attractiveness drug targets. target isoniazid, key            10 27 strains deletion allele (Fig. 2). fact antitubercular agent, mycolic acid biosynthesis (21).              chromosomal deletion obtained presence
FAS II required elongation mycolic acids             functional copy formal genetic proof fabG1 predicted essential cellular component.              essential gene culture conditions. majority individual enzymes make                  â€œdelinquentâ€? strain, Mess 19 (fabG1âŒ¬ [fabG1 inhA hemZ gm
FAS II elongation identified (6, 7),          L5 int]) (Table 1), analyzed Southern hybridization confirmed InhA KasA required                   used study.
cellular survival integrity M. smegmatis (4, 31).                 Functional complementation M. smegmatis fabG. Differ-  contradictory findings raised            ent bacterial species produce structural variants mycolic possibility certain enzymes FAS II cycle          acids. example, M. smegmatis produces ethylenic â?£-, â?£â¬˜-, essential. findings include prediction based              epoxy-mycolic acids different lengths, M.
transposon mutagenesis inhA fabG1 required               tuberculosis synthesizes cyclopropanated â?£-, methoxy-, growth M. tuberculosis (25) isolation myco-             keto-mycolic acids. addition, oxygenated mycolates bacterial mutants defective mycolic acid synthesis (3, 18).         longer M. tuberculosis M. smegmatis (32). addition, genes encoding potential homologs              known FAS II enzymes control chain length, FabG (FabG2 FabG5), overlapping func-                   probable structural limitation tions, identified M. tuberculosis genome (7).            length fatty acid accommodated active
   order determine fabG1 essential vitro,          site FAS II enzymes (20). addition, protein-protein
used step method try generate deletion strain               interactions FabG members FAS II
(23). suicide delivery vector containing unmarked                 complex demonstrated (30). wanted deter-
frame deletion allele fabG1 constructed used                FabG enzyme plays role determining
electroporate M. tuberculosis (Fig. 1). deletion allele         chain length mycolic acid type. determined unmarked frame, polar effects expression             M. smegmatis fabG gene complement fabG1
inhA hemZ expected. Single-crossover strains                 defect M. tuberculosis. isolated entire vector incorporated                 previously demonstrated high-efficiency replace-
homologous recombination. strain (Mess 4) (Table 1)               ment L5-based integrating vectors occurs M. tuberculosis
verified Southern blotting used isolate double-             (22, 24). used â€œswitchingâ€? technique test fabG ho-
crossover strains. screened 40 strains PCR                  mologues species order determine determine wild-type deletion allele fabG1.          functional M. tuberculosis. basic premise wild-type allele, indicating            method efficiently replace resident inte- isolate mutant. merodiploid strain constructed             grated vector, carried functional copy fabG1,
transforming single-crossover strain Mess 4 L5               transformation selection second version integrating plasmid pMabA-HemZ-Int carrying M. tuber-                 integrating vector carrying alternative alleles. incoming
culosis complete operon (fabG1, inhA, hemZ)                  allele functional, obtain viable cells; native promoter. merodiploid background, able              switched strains obtained. isolate wild-type deletion double-crossover strains;              confirmed switching method worked effi-
 3724     PARISH ET AL.                                                                                                                      J. BACTERIOL.




   FIG. 2. Genomic analyses recombinant strains.   Restriction maps chromosomal wild-type deletion alleles fabG1. expected
sizes fragments indicated maps positions probes used. (B) Switching M. smegmatis fabG. Genomic DNA digested XhoI. Lanes 1 4, switched strains carrying M. smegmatis fabG M. tuberculosis fabG1 deleted; lane 5, wild type.
fabG-msm, M. smegmatis fabG; fabG1-wt, wild-type fabG1. (C) Switching E. coli fabG. Genomic DNA digested BamHI. Lane 1,
lambda HindIII marker; lanes 2 4, cointegrated strains Mess 30, Mess 31, Mess 32 carrying M. tuberculosis wild-type E. coli fabG genes.
(D) PCR amplification E. coli fabG cointegrated strains. Lane 1, Mess 30; lane 2, Mess 31; lane 3, Mess 32; lane 4, lambda HindIII marker.
fabG Ec, E. coli fabG. expected product size (0.9 kb) product identity confirmed sequencing.



ciently. plasmids carrying complete M. tuberculosis              confirming fabG1 required fabG1-hemZ operon different resistance markers (gm, kan,               polar effects inhA hemZ. hyg) used. Transformation delinquent strain                   examined functional complementation M. smeg-
Mess 19 (fabG1âŒ¬ [fabG1 inhA hemZ gm L5 int])               matis FabG. M. smegmatis fabG (fabGMsm) cloned pDUCK1 (fabG1 inhA hemZ kan L5 int) pDUCK2 (fabG1
inhA hemZ hyg L5 int) vector resulted high-efficiency vector
replacement (Table 2). confirm vector replacement                     TABLE 2. Functional complementation M. tuberculosis cointegration occurred, 24 samples                                         fabG homologs
transformant patch tested gentamicin resistance,                                                                  Antibiotic   Transformation gentamicin sensitive, confirming original plas-           Strain       Plasmid             Allele
                                                                                                                               selection      efficiencya
mid lost. transformant obtained switching
                                                                           Mess   19   pUC-Hyg-Int                       Hygromycin          10
plasmid selected study. genotypes                   Mess   19   pDUCK1        M. tuberculosis operon   Kanamycin         1 â«» 105
strains Mess 25 (fabG1âŒ¬ [fabG1 inhA hemZ kan L5 int])                  Mess   19   pDUCK2        M. tuberculosis operon   Hygromycin        2 â«» 106
                                                                           Mess   25   pDUCK8        M. tuberculosis fabG1    Hygromcyin      1.7 â«» 105
Mess 26 (fabG1âŒ¬ [fabG1 inhA hemZ hyg L5 int])                     Mess   26   pDUCK9        M. smegmatis fabG        Gentamicin        1 â«» 105
firmed Southern hybridization  shown).                  Mess   26   pDUCK15       E. coli (Ts)             Gentamicinb          1
                                                                           Mess   26   pDUCK16       E. coli                  Gentamicinb          1
firmed complementation performed using                   Mess   26   pDUCK18       E. coli (Ts)             Gentamicinb          2
fabG1 gene  Transformation Mess 25 (containing                                                                                                   Transformation efficiencies plasmids expressed number M. tuberculosis fabG1 [fabG1Mtb] operon) pDUCK8                   transformants â?®g plasmid DNA.
taining fabG1Mtb) occurred high efficiency (Table 2),               b
                                                                                Transformants isolated 30Â°C.
 VOL. 189, 2007                                                                   FUNCTIONAL COMPLEMENTATION fabG1                        3725




  FIG. 3. Multiple-sequence alignment fabG alleles. fabG genes M. tuberculosis H37Rv (Mtb), M. smegmatis (Msm), E. coli (Eco) aligned using Clustal (www.ebi.ac.uk).

 promoter integrating vector obtain plasmid                  acids synthesized using type II FAS   ho-
pDUCK9 (fabGMsm gm L5 int) transformed strain                     mologs mycobacterial FAS II enzymes, including FabG,
Mess 26 (fabG1âŒ¬ [fabG1 inhA hemZ hyg L5 int]). Gentamicin-                 present E. coli (Fig. 3). tested ability E. coli
resistant transformants obtained high frequency (Ta-             fabG (fabGEc) complement M. tuberculosis fabG1. Vec-
ble 2) tested determine sensitivities hygromycin           tors carrying fabGEc expressed mycobacterial pro-
(24 24 transformants Gmr Hygs). PCR Southern                   moter constructed. tested E. coli alleles, analysis used confirm expected genotypes trans-             encoding protein normal activity (FabGA154T) formants carrying deletion allele M. tuberculosis               encoding temperature-sensitive derivatives (FabGE233K
fabG1 gene functional copy M. smegmatis fabG (Fig.                FabGE233K,A154T), nonpermissive
2). results confirmed M. smegmatis gene able              42Â°C E. coli (16). reasoned E. coli allele complement function M. tuberculosis gene.                    functional, able construct temperature-sen-
  Lack functional complementation E. coli fabG. Fatty                sitive strain M. tuberculosis. Electroporation Mess 26
acid biosynthesis critical metabolic process bacteria.         (fabG1âŒ¬ [fabG1 inhA hemZ hyg L5 int]) plasmids E. coli does produce mycolic acids, fatty               pDUCK15, pDUCK16, pDUCK18 resulted low




   FIG. 4. Growth recombinant M. tuberculosis strains: growth M. tuberculosis wild type (WT), Mess 25 ([fabG1 inhA hemZ]Mtb), Mess 27
(fabGMsm), Mess 29 (fabGMtb) liquid culture. data averages â«¾ standard deviations cultures. Growth curves constructed times, similar results obtained.
   FIG. 5. Mycolic acid analyses: TLC mycolates   MALDI-TOF mass spectra purified â?£-mycolates (B), methoxy-mycolates (C), keto-mycolates different strains M. tuberculosis expressing FabG1 M. tuberculosis (Mtb), M. smegmatis (Msm), E. coli (Eco).
TLC performed eluent (petroleum ether-diethyl ether, 9:1 [vol/vol]; runs). Lipid spots revealed spraying plates molybdophosphoric acid (10  ethanol), followed charring.


                                                                      3726
 VOL. 189, 2007                                                              FUNCTIONAL COMPLEMENTATION fabG1                                  3727


frequencies transformation organisms selected          enzymes FAS II pathway interact form gentamicin 30Â°C (Table 2). suggested vector         complex (30), possibility.
replacement occurred. PCR amplification using prim-            Conclusions. confirmed fabG1 essential gene
ers specific M. tuberculosis E. coli gene (Fig.   using robust genetic methods. conclusion contrasts 3D), followed sequencing, revealed case         prediction based transposon mutagenesis results. 
strain copy gene, indicating incoming         transposon method predicts essentiality does
plasmid cointegrated L5 site  occurred      result percentage false negatives. example, low frequency). Southern analysis confirmed presence       transposon insertion occurred near 3â¬˜ end gene, functional fabG1Mtb gene (Fig. 3C). transformation         result partially fully functional proteins. procedure repeated, results obtained.         data confirm fabG1 essential fabG ho- results indicated E. coli FabG complement         mologs able complement function normal defect fabG1 gene M. tuberculosis. wild-      culture conditions.  stage say
type gene nonfunctional, able isolate tem-       lack expression genes perature-sensitive mutants.                                         lack required enzymatic activity FabG proteins.
   Phenotypic consequences FabG replacement.            equivalence M. smegmatis homolog demon-
replacement native M. tuberculosis fabG1 gene M.      strated fact changes viability mycolic acid
smegmatis fabG homolog resulted viable cells,       structure observed functional copy possible changes mycolic acid biosynthesis cell      cell fabGMsm. contrast, E. coli fabG functional;
wall structure occurred. investigated number pheno-         unlikely related lack expression, types indicated cell wall          provided mycobacterial promoter expression. changes mycolic acid profiles recombinant            likely structure E. coli enzyme able
strains.                                                            accommodate long-chain fatty acids protein-
   differences colony morphology sensitivity        protein interactions necessary FAS II detergent sodium dodecyl sulfate isoniazid  liquid media      function disrupted (20, 30). solid media) strains carrying fabGMtb strains carrying fabGMsm observed (data shown).                                   ACKNOWLEDGMENTS
addition, differences growth rate liquid medium          G.R. funded GlaxoSmithKline Action TB Initiative. observed (Fig. 4). specificity FabG relation      work mycolic acids partially funded grant QLK2-CT-2000- type, length, quantity mycolic acids synthesized     01761 European Community. investigated. Strains carrying fabG1Mtb fabGMsm         thank J. Cronan providing plasmids pCL33, pCL79,                                                                     pCL80. fabG1Mtb fabGEc grown medium lacking
Tween 80, total mycolic acid profiles generated (Fig.                                       REFERENCES
5). TLC analysis mycolates different strains         1. Banerjee, , M. Sugantino, J. C. Sacchettini, W. R. Jacobs. 1998. showed mycolates produced (Fig. 5A).             mabA gene inhA operon Mycobacterium tuberculosis encodes                                                                         3-ketoacyl reductase fails confer isoniazid resistance. Microbiology types mycolates purified various strains,        144:2697â€“2704. lengths determined MALDI-TOF mass spec-            2. Betts, J. C.,  McLaren, M. G. Lennon, F. M. Kelly, P. T. Lukey, S. J.
trometry (17). Superimposable mass spectra obtained            Blakemore, K. Duncan. 2003. Signature gene expression profiles dis-
                                                                        criminate isoniazid-, thiolactomycin-, triclosan-treated Myco- different â?£-mycolates (Fig. 5B), methoxy-mycolates (Fig.            bacterium tuberculosis. Antimicrob. Agents Chemother. 47:2903â€“2913.
5C), keto-mycolates (Fig. 5D). pseudomolecular mass          3. Bhakta, S., G. S. Besra,  M. Upton, T. Parish, C. Sholto-Douglas-Vernon,
(Mâ«¹Na)â«¹ peaks observed spectra corresponded               K. J. C. Gibson, S. Knutton, S. Gordon, R. P. daSilva, M. C. Anderton,                                                                         E. Sim. 2004. Arylamine N-acetyltransferase required synthesis peaks determined previously mycolates synthesized            mycolic acids complex lipids Mycobacterium bovis BCG represents wild-type strain M. tuberculosis (strain H37Rv) (10).         novel drug target. J. Exp. Med. 199:1191â€“1199.
                                                                     4. Bhatt, , L. Kremer,   Dai, J. C. Sacchettini, W. R. Jacobs. 2005.
additional lipid spots structural changes transfor-           Conditional depletion KasA, key enzyme mycolic acid biosynthesis,
mants detected TLC MALDI-TOF mass spec-                     leads mycobacterial cell lysis. J. Bacteriol. 187:7596â€“7606.
trometry (data shown).                                           5. Brennan, P. J. 2003. Structure, function, biogenesis cell wall                                                                         Mycobacterium tuberculosis. Tuberculosis 83:91â€“97.
   results indicated M. smegmatis FabG protein        6. Camus, J. C., M. J. Pryor, C. Medigue, S. T. Cole. 2002. annotation functionally equivalent M. tuberculosis FabG1 protein         genome sequence Mycobacterium tuberculosis H37Rv. Microbiology
                                                                        148:2967â€“2973. utilize endogenous substrates normally.             7. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V.
FabG does define length fatty acid chains.            Gordon, K. Eiglmeier, S. Gas, C. E. Barry, F. Tekaia, K. Badcock, D.
addition, interference FabG1 function          Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T.
                                                                        Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornby, K. Jagels,  Krogh,
cells contained E. coli enzyme.                          J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M.  Quail, M. 
   Unusually, strain carrying complete M. tuberculosis          Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S.
operon integrated vector (Mess 25) grew slower          Squares, J. E. Sulston, K. Taylor, S. Whitehead, B. G. Barrell. 1998.
                                                                        Deciphering biology Mycobacterium tuberculosis complete
strain carrying fabG1 (Mess 29) grew (Fig. 4). rea-           genome sequence. Nature 393:537â€“544.
son difference immediately obvious,      8. Daffe, M., P. Draper. 1998. envelope layers mycobacteria                                                                         reference pathogenicity. Adv. Microb. Physiol. 39:131â€“203.
difference indicate relative amounts fabG1         9. Daffe, M., M.  LaneÂ´elle, C. Asselineau, V. LeÂ´vy-FreÂ´bault, H. L. David. inhA important; strain carrying complete                1983. Inte t taxonomique des acides gras des MycobacteÂ´ries: proposition
operon functional copies inhA                dâ€™une thode dâ€™analyse. Ann. Microbiol. Inst. Pasteur 134:241â€“256.
                                                                    10. DaffeÂ´, M., M.  LaneÂ´elle, P. L. Valero-Guillen. 1988. Tetraenoic expected produce enzyme strain car-            pentaenoic mycolic acids Mycobacterium thamnopheos. Structure, tax-
rying fabG1 (containing functional copy gene).          onomic biosynthetic implications. Eur. J. Biochem. 177:339â€“344.
 3728        PARISH ET AL.                                                                                                                                 J. BACTERIOL.

11. Ducasse-Cabanot, S., M. Cohen-Gonsaud, H. Marrakchi, M. Nguyen, D.                  22. Parish, T., M. Schaeffer, G. Roberts, K. Duncan. 2005. HemZ essen-
    Zerbib, J. Bernadou, M. Daffe, G. Labesse,  Quemard. 2004. vitro               tial growth Mycobacterium tuberculosis. Tuberculosis 85:197â€“204.
    inhibition Mycobacterium tuberculosis beta-ketoacyl-acyl carrier pro-        23. Parish, T., N. G. Stoker. 2000. Use flexible cassette method     tein reductase MabA isoniazid. Antimicrob. Agents Chemother. 48:242â€“                 generate double unmarked Mycobacterium tuberculosis tlyA plcABC mutant
    249.                                                                                    gene replacement. Microbiology 146:1969â€“1975.
12. Hayashi, T., O. Yamamoto, H. Sasaki, H. okazaki,  Kawaguchi. 1984.            24. Pashley, C. , T. Parish. 2003. Efficient switching mycobacteriophage
    Inhibition fatty acid synthesis antibiotic thiolactomycin. J. Antibiot.       L5-based integrating plasmids Mycobacterium tuberculosis. FEMS Micro-
    37:1456â€“1461.                                                                           biol. Lett. 229:211â€“215.
13. Heym, B., P. M. Alzari, N. Honore, S. T. Cole. 1995. Missense mutations         25. Sassetti, C. M., D. H. Boyd, E. J. Rubin. 2003. Genes required     catalase-peroxidase gene, katG, associated isoniazid resis-             mycobacterial growth defined high density mutagenesis. Mol. Microbiol.
    tance Mycobacterium tuberculosis. Mol. Microbiol. 15:235â€“245.                        48:77â€“84.
14. Jackson, M., C. Raynaud, M.  Laneelle, C. Guilhot, C. LaurentWinter, D.           26. Schaeffer, M. L., G. Agnihotri, C. Volker, H. Kallender, P. J. Brennan,     Ensergueix, B. Gicquel, M. Daffe. 1999. Inactivation antigen 85C             J. T. Lonsdale. 2001. Purification biochemical characterization     gene profoundly affects mycolate content alters permeability             Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases
    Mycobacterium tuberculosis cell envelope. Mol. Microbiol. 31:1573â€“                  KasA KasB. J. Biol. Chem. 276:47029â€“47037.
    1587.                                                                               27. Slayden, R. , R. E. Lee, J. W. Armour,  M. Cooper,  M. Orme, P. J.
15. Kremer, L., J. D. Douglas,  Baulard, C. Morehouse, M. R. Guy, D. Alland,              Brennan, G. S. Besra. 1996. Antimycobacterial action thiolactomycin:
    L. G. Dover, J. H. Lakey, W. R. Jacobs, P. J. Brennan, D. E. Minnikin,              inhibitor fatty acid mycolic acid synthesis. Antimicrob. Agents
    G. S. Besra. 2000. Thiolactomycin related analogues novel anti-                  Chemother. 40:2813â€“2819.
    mycobacterial agents targeting KasA KasB condensing enzymes                  28. Stover, C. K., V. F. Delacruz, T. R. Fuerst, J. E. Burlein, L.  Benson, L. T.
    Mycobacterium tuberculosis. J. Biol. Chem. 275:16857â€“16864.                             Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull, S. B. Snapper,
16. Lai, C.-Y., J. E. Cronan. 2004. Isolation characterization â?¤-                R. G. Barletta, W. R. Jacobs, B. R. Bloom. 1991. New use BCG     ketoacyl-acyl carrier protein reduc